Heidelberg Pharma Management
Management criteria checks 3/4
We currently do not have sufficient information about the CEO.
Key information
Andreas Pahl
Chief executive officer
€328.3k
Total compensation
| CEO salary percentage | 73.1% |
| CEO tenure | less than a year |
| CEO ownership | n/a |
| Management average tenure | 1.1yrs |
| Board average tenure | 11.9yrs |
Recent management updates
Recent updates
Is Heidelberg Pharma (ETR:HPHA) A Risky Investment?
Feb 16
Heidelberg Pharma AG's (ETR:HPHA) Price In Tune With Revenues
Dec 05Industry Analysts Just Upgraded Their Heidelberg Pharma AG (ETR:HPHA) Revenue Forecasts By 21%
Jul 21Analyst Forecasts For Heidelberg Pharma AG (ETR:HPHA) Are Surging Higher
Oct 16Heidelberg Pharma (ETR:HPHA) Will Have To Spend Its Cash Wisely
Nov 28Heidelberg Pharma AG (ETR:HPHA) Analysts Are More Bearish Than They Used To Be
Mar 27We Think Heidelberg Pharma (ETR:HPHA) Needs To Drive Business Growth Carefully
Mar 15Investors Who Bought Heidelberg Pharma (ETR:HPHA) Shares Five Years Ago Are Now Up 245%
Jan 17
We Think Heidelberg Pharma (ETR:HPHA) Needs To Drive Business Growth Carefully
Dec 14CEO Compensation Analysis
| Date | Total Compensation | Salary | Company Earnings |
|---|---|---|---|
| Feb 29 2024 | n/a | n/a | -€18m |
| Nov 30 2023 | n/a | n/a | -€20m |
| Aug 31 2023 | n/a | n/a | -€22m |
| May 31 2023 | n/a | n/a | -€27m |
| Feb 28 2023 | n/a | n/a | -€19m |
| Nov 30 2022 | €328k | €240k | -€20m |
| Aug 31 2022 | n/a | n/a | -€21m |
| May 31 2022 | n/a | n/a | -€22m |
| Feb 28 2022 | n/a | n/a | -€27m |
| Nov 30 2021 | €442k | €240k | -€26m |
| Aug 31 2021 | n/a | n/a | -€25m |
| May 31 2021 | n/a | n/a | -€22m |
| Feb 28 2021 | n/a | n/a | -€20m |
| Nov 30 2020 | €295k | €207k | -€18m |
| Aug 31 2020 | n/a | n/a | -€17m |
| May 31 2020 | n/a | n/a | -€15m |
| Feb 29 2020 | n/a | n/a | -€12m |
| Nov 30 2019 | €288k | €200k | -€10m |
| Aug 31 2019 | n/a | n/a | -€10m |
| May 31 2019 | n/a | n/a | -€11m |
| Feb 28 2019 | n/a | n/a | -€12m |
| Nov 30 2018 | €286k | €200k | -€12m |
| Aug 31 2018 | n/a | n/a | -€11m |
| May 31 2018 | n/a | n/a | -€11m |
| Feb 28 2018 | n/a | n/a | -€11m |
| Nov 30 2017 | €241k | €171k | -€11m |
Compensation vs Market: Andreas's total compensation ($USD352.15K) is below average for companies of similar size in the German market ($USD705.27K).
Compensation vs Earnings: Andreas's compensation has been consistent with company performance over the past year.
CEO
Andreas Pahl
less than a year
Tenure
€328,276
Compensation
Prof. Dr. Andreas Pahl is Chief Executive Officer & Spokesman of the Executive Board at Heidelberg Pharma AG since February 1, 2024 and had been its Chief Scientific Officer and Member of the Executive Man...
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| CEO & Spokesman of the Executive Board | less than a year | €328.28k | no data | |
| Chief Financial Officer | less than a year | no data | no data | |
| Chief Operating Officer | 1.3yrs | no data | no data | |
| Director Corporate Communication | no data | no data | no data | |
| Chief Medical Officer | 3.1yrs | no data | no data | |
| Chief Business Officer | no data | no data | no data |
1.1yrs
Average Tenure
Experienced Management: HPHA's management team is not considered experienced ( 1.1 years average tenure), which suggests a new team.
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Member of the Supervisory Board | 19yrs | €24.77k | no data | |
| Deputy Chairman of the Supervisory Board | 24.3yrs | €40.25k | no data | |
| Chairman of Supervisory Board | 13.9yrs | €52.50k | no data | |
| Member of the Supervisory Board | 11.9yrs | €27.33k | no data | |
| Deputy Chairman of Supervisory Board | 8.8yrs | €35.50k | no data | |
| Member of Supervisory Board | 1.8yrs | €5.08k | no data | |
| Member of Supervisory Board | less than a year | no data | no data |
11.9yrs
Average Tenure
58.5yo
Average Age
Experienced Board: HPHA's board of directors are seasoned and experienced ( 11.9 years average tenure).